Publications by authors named "Christopher Wynne"

Claim this Profile
S
Safety, Pharmacokinetics and Preliminary Efficacy of IL4-Rα Monoclonal Antibody AK120 in Both Healthy and Atopic Dermatitis Subjects: A Phase I, Randomized, Two-Part, Double-Blind, Placebo-Controlled, Dose-Escalation, First-In-Human Clinical Study.
Christopher John Wynne, Alexandra Cole, Charlotte Lemech, Guoqin Wang, Yu Zhang

Dermatol Ther (Heidelb)· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized, double-blind, 3-arm, parallel study assessing the pharmacokinetics, safety, tolerability and immunogenicity of AVT04, an ustekinumab candidate biosimilar, in healthy adults.
Christopher Wynne, Paul Hamilton, Kristi McLendon, Heimo Stroissnig, Matthew Smith

Expert Opin Investig Drugs· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A multicenter, randomized, open-label, 2-arm parallel study to compare the pharmacokinetics, safety and tolerability of AVT02 administered subcutaneously via prefilled syringe or autoinjector in healthy adults.
Christopher Wynne, Christian Schwabe, Heimo Stroissnig, Roshan Dias, Joanna Sobierska

Expert Opin Biol Ther· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized, adaptive design, double-blind, 3-arm, parallel study assessing the pharmacokinetics and safety of AVT02, a high-concentration (100 mg/mL) Adalimumab biosimilar, in healthy adult subjects (ALVOPAD FIRST).
Christopher Wynne, Christian Schwabe, Charlotte Lemech, Heimo Stroissnig, Roshan Dias

Expert Opin Investig Drugs· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized, single-blind, Phase I trial (INVICTAN-1) assessing the bioequivalence and safety of BI 695502, a bevacizumab biosimilar candidate, in healthy subjects.
Willem Hettema, Christopher Wynne, Benjamin Lang, Mario Altendorfer, Niklas Czeloth

Expert Opin Investig Drugs· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bioequivalence, safety and immunogenicity of BI 695501, an adalimumab biosimilar candidate, compared with the reference biologic in a randomized, double-blind, active comparator phase I clinical study (VOLTAIRE®-PK) in healthy subjects.
Christopher Wynne, Mario Altendorfer, Ivo Sonderegger, Lien Gheyle, Rod Ellis-Pegler

Expert Opin Investig Drugs· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The cathepsin K inhibitor odanacatib suppresses bone resorption in women with breast cancer and established bone metastases: results of a 4-week, double-blind, randomized, controlled trial.
Anders Bonde Jensen, Christopher Wynne, Guillermo Ramirez, Weili He, Yang Song

Clin Breast Cancer· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lack of progress in New Zealand's Cancer Control Strategy.
Christopher Wynne

N Z Med J· August 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of an integrated continuing medical education (CME) and quality improvement (QI) program on radiation oncologist (RO) clinical practice.
Cheng Nang Leong, Thomas Philip Shakespeare, Rahul K Mukherjee, Michael F Back, Khai Mun Lee, Christopher J Wynne

Int J Radiat Oncol Biol Phys· December 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A study of complications arising from different methods of anesthesia used in high-dose-rate brachytherapy for cervical cancer.
Keith H C Lim, Jiade J Lu, Christopher J Wynne, Michael F Back, Rahul Mukherjee

Am J Clin Oncol· October 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of a radiotherapy protocol based on INT0116 for completely resected gastric adenocarcinoma.
Hans T Chung, Thomas P Shakespeare, Christopher J Wynne, Jay J Lu, Rahul K Mukherjee

Int J Radiat Oncol Biol Phys· August 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design of an internationally accredited radiation oncology resident training program incorporating novel educational models.
Thomas Philip Shakespeare, Michael Frederick Back, Jiade Jay Lu, Christopher John Wynne, Leah Bloomfield

Int J Radiat Oncol Biol Phys· July 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A comparison of RANZCR and Singapore-designed radiation oncology practice audit instruments: how does reproducibility affect future approaches to revalidation?
Thomas P Shakespeare, Rahul K Mukherjee, Jiade J Lu, Christopher J Wynne, Mahesh B Kumar

Australas Radiol· June 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjuvant high-dose rate brachytherapy after chemoradiation for treatment of early T-stage nasopharyngeal carcinoma.
Jiade J Lu, Thomas Shakespeare, Boon Cher Goh, Chua Eu Tiong, Michael Back, Christopher J Wynne

Am J Clin Oncol· April 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient preference for radiotherapy fractionation schedule in the palliation of painful bone metastases.
Thomas P Shakespeare, Jiade J Lu, Michael F Back, Shen Liang, Rahul K Mukherjee, Christopher J Wynne

J Clin Oncol· June 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cultural attitudes to cancer management in traditional South-East Asian patients.
K Jane Ong, Michael F Back, Jiade J Lu, Thomas S Shakespeare, Christopher J Wynne

Australas Radiol· December 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis